The HAMLETT study focuses on patients who have experienced a first episode of psychosis and are currently in remission, meaning their symptoms have improved or disappeared. The study examines the effects of continuing versus reducing or stopping the use of antipsychotic medication after this initial recovery. The medications being studied include Haloperidol, Clozapine, Tiapride, Sertindole, Paliperidone, Olanzapine, Sulpiride, Aripiprazole, Lurasidone, Risperidone, Amisulpride, Chlorpromazine, Pimozide, and Quetiapine. The purpose of the study is to understand how these different approaches affect personal and social functioning over both the short term (1-2 years) and long term (3-4 years).

Participants in the study will be randomly assigned to either continue their current antipsychotic medication or to gradually reduce or stop it. The study will monitor various aspects of their health and well-being, including any side effects from the medication, overall quality of life, and any changes in their physical and mental health. The study will also look at how these changes affect their ability to function in daily life, including their social interactions and personal well-being.

The study will take place over several years, with regular check-ins to assess the participants’ progress. The primary focus is on long-term social recovery, which is considered important by both patients and their families. Additional factors being monitored include the severity of any remaining symptoms, physical health indicators like body mass index, and any instances of aggression or self-harm. The study aims to provide valuable insights into the best treatment strategies for individuals recovering from a first episode of psychosis.